AzurRx BioPharma, Inc. (NASDAQ:AZRX) is a biopharmaceutical company specializing in the development of therapeutic proteins for the treatment of patients with gastrointestinal disorders. Its lead product candidate is MS1819, a recombinant lipase that is being studied for the treatment of exocrine pancreatic insufficiency (EPI) associated with cystic fibrosis (CF) and chronic pancreatitis (CP). AzurRx is pursuing parallel clinical pathways – a Phase 2b monotherapy clinical trial and a Phase 2 combination therapy trial. The Company is headquartered in New York, NY, with scientific operations based in Langlade, France and clinical operations in Hayward, California.